Qingdao Baheal Medical INC. (SHE:301015)
China · Delayed Price · Currency is CNY 22.73
-0.64 (-2.74%)
May 28, 2026, 3:04 PM CST
SHE:301015 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Operating Revenue | 7,423 | 7,480 | 8,068 | 8,226 | 7,494 | 7,030 |
Other Revenue | 26.67 | 26.67 | 26.03 | 29.96 | 15.19 | 22 |
| 7,449 | 7,507 | 8,094 | 8,256 | 7,510 | 7,052 | |
Revenue Growth (YoY) | -7.89% | -7.26% | -1.96% | 9.94% | 6.50% | 19.94% |
Cost of Revenue | 4,639 | 4,741 | 5,228 | 5,505 | 5,426 | 5,277 |
Gross Profit | 2,811 | 2,766 | 2,866 | 2,751 | 2,084 | 1,774 |
Selling, General & Admin | 1,988 | 1,947 | 1,797 | 1,595 | 1,319 | 1,130 |
Research & Development | 41.93 | 42.17 | 36.14 | 42.45 | 3.32 | - |
Other Operating Expenses | 56.35 | 45.6 | 39.3 | 27.94 | 36.05 | 31.54 |
Operating Expenses | 2,093 | 2,042 | 1,884 | 1,698 | 1,371 | 1,160 |
Operating Income | 717.75 | 723.41 | 981.91 | 1,053 | 712.6 | 614.75 |
Interest Expense | -110.52 | -103.65 | -80.09 | -71.73 | -58.07 | -61.08 |
Interest & Investment Income | 29.35 | 30.68 | 72.84 | 57.03 | 9.44 | 10.92 |
Currency Exchange Gain (Loss) | -12.87 | -12.87 | -2.88 | -2.9 | 6.42 | -2.38 |
Other Non Operating Income (Expenses) | 0.26 | -1.89 | -12.93 | -8.9 | -4.99 | -15.22 |
EBT Excluding Unusual Items | 623.97 | 635.67 | 958.86 | 1,026 | 665.4 | 547 |
Gain (Loss) on Sale of Investments | 112.85 | 73.36 | -6.59 | 0.62 | -10.75 | 5.87 |
Gain (Loss) on Sale of Assets | 0.54 | 0.52 | 0.93 | -6.57 | 0.57 | 0.1 |
Asset Writedown | 22.37 | -0.6 | -0.46 | -0.35 | -0.04 | -0.01 |
Other Unusual Items | 13.57 | 14.03 | 13.89 | 8.26 | 13.38 | 12.46 |
Pretax Income | 773.3 | 722.98 | 966.63 | 1,028 | 668.55 | 565.42 |
Income Tax Expense | 155.58 | 151.05 | 199.6 | 257.26 | 183.15 | 150.4 |
Earnings From Continuing Operations | 617.72 | 571.93 | 767.03 | 770.73 | 485.4 | 415.02 |
Minority Interest in Earnings | -104.11 | -97.24 | -75.44 | -58.67 | 16.68 | 6.63 |
Net Income | 513.61 | 474.69 | 691.59 | 712.06 | 502.09 | 421.64 |
Net Income to Common | 513.61 | 474.69 | 691.59 | 712.06 | 502.09 | 421.64 |
Net Income Growth | -13.00% | -31.36% | -2.87% | 41.82% | 19.08% | 54.61% |
Shares Outstanding (Basic) | 524 | 527 | 524 | 524 | 523 | 496 |
Shares Outstanding (Diluted) | 535 | 533 | 540 | 535 | 523 | 496 |
Shares Change (YoY) | -0.18% | -1.29% | 0.92% | 2.37% | 5.44% | 5.50% |
EPS (Basic) | 0.98 | 0.90 | 1.32 | 1.36 | 0.96 | 0.85 |
EPS (Diluted) | 0.96 | 0.89 | 1.28 | 1.33 | 0.96 | 0.85 |
EPS Growth | -12.85% | -30.47% | -3.76% | 38.54% | 12.94% | 46.55% |
Free Cash Flow | 348.15 | 645.52 | 509.86 | 614.01 | 200.43 | 153.81 |
Free Cash Flow Per Share | 0.65 | 1.21 | 0.94 | 1.15 | 0.38 | 0.31 |
Dividend Per Share | 0.571 | 0.571 | 0.762 | - | 0.762 | 0.667 |
Dividend Growth | -25.07% | -25.07% | - | - | 14.24% | - |
Gross Margin | 37.73% | 36.84% | 35.41% | 33.32% | 27.75% | 25.16% |
Operating Margin | 9.63% | 9.64% | 12.13% | 12.75% | 9.49% | 8.72% |
Profit Margin | 6.89% | 6.32% | 8.54% | 8.63% | 6.69% | 5.98% |
Free Cash Flow Margin | 4.67% | 8.60% | 6.30% | 7.44% | 2.67% | 2.18% |
EBITDA | 788.53 | 792.61 | 1,045 | 1,110 | 735.93 | 636.6 |
EBITDA Margin | 10.59% | 10.56% | 12.91% | 13.45% | 9.80% | 9.03% |
D&A For EBITDA | 70.78 | 69.2 | 62.89 | 57.65 | 23.33 | 21.85 |
EBIT | 717.75 | 723.41 | 981.91 | 1,053 | 712.6 | 614.75 |
EBIT Margin | 9.63% | 9.64% | 12.13% | 12.75% | 9.49% | 8.72% |
Effective Tax Rate | 20.12% | 20.89% | 20.65% | 25.03% | 27.39% | 26.60% |
Revenue as Reported | 7,449 | 7,507 | 8,094 | 8,256 | 7,510 | 7,052 |
Advertising Expenses | - | - | - | - | 1.01 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.